In addition, the combination of the two inhibitors, cystatin C and stefin A, could further stratify the risk of adverse event as was the case with stefin B and cathepsin B in colorectal cancer (Kos et al, 2000a). The gene discussed is CST3; the disease is colorectal cancer.